Breast Cancer Coverage from Every Angle

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

In heavily pretreated patients with metastatic triple-negative breast cancer, the antibody-drug conjugate sacituzumab govitecan was well tolerated and induced early and durable responses, according to a study in the Journal of Clinical Oncology. This agent targets Trop-2, which is expressed in most triple-negative breast cancers. Based on these early findings, the investigators conclude that Trop-2 warrants further research as a therapeutic target and predictive biomarker.

In a single-arm, multicenter trial of 69 patients with relapsed or refractory metastatic triple-negative breast cancer, the confirmed objective response rate was 30%, with 19 partial responses and 2 complete responses. The median duration of response was 8.9 months (95% confidence interval, 6.1–11.3 months), and the clinical benefit rate (complete response plus partial response plus stable disease ≥ 6 months) was 46%. And these responses occurred early, with a median onset of 1.9 months.

As for toxicity, grade ≥ 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and diarrhea (13%). The incidence of febrile neutropenia was 7%.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.